Analysis of Circulating DNA in Blood Samples of Glioma-affected Patients

Launched by CORPORACION PARC TAULI · Jul 19, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to diagnose gliomas, which are a type of brain tumor, by looking for pieces of tumor DNA in the blood of patients. Instead of relying only on traditional tissue samples taken through surgery, this study aims to make the diagnosis process less invasive and quicker by using a method called a liquid biopsy. Researchers will analyze blood samples using a specialized technique that can detect very small amounts of tumor DNA, helping to confirm the diagnosis and understand the tumor better.

To participate in this trial, you need to be at least 18 years old and have a brain lesion that doctors believe might be a glioma, as shown on MRI scans. You also need to agree to have a standard surgical procedure to remove the lesion. It's important to note that this study is not open to pregnant or breastfeeding women, and those who cannot have surgery for other reasons may not qualify. If you join the trial, you'll help researchers improve the diagnosis of gliomas, which could lead to faster and more personalized treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years.
• • De novo primary brain lesion, compatible with a glioma according to contrast-enhanced magnetic resonance images. The injury must be treated by the usual surgical procedure.
• • Signature of informed consent.
• Exclusion Criteria:
• • Pregnant or breastfeeding women.
• • Reasonable doubts in the diagnosis of glioma by magnetic resonance, or patients whose tissue biopsy diagnoses a brain lesion other than a glioma.
• • Patients who cannot undergo surgical resection, or when the tissue samples taken are not significant enough to be analyzed.
• • Inability or disagreement with signing the informed consent.